Skip to main content



Local Cdiff information for Texas

Texas

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Texas.



Local Cdiff information for Texas

Texas

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Texas.

Providers

Mike Bismar, MD, FACG

Texas Health Huguley Hospital
Medical Office Building 3
11801 South Freeway,
Suite 140
Burleson, Texas 76028

(817) 551-6161

VISIT WEBSITE>

Dr. Herbert L. DuPont, MD

Chief, Internal Medicine Service
St. Luke’s Medical Clinic
1200 Pressler, Suite E733
Houston, 77030
(713) 500-9366
EMAIL DR. DUPONT >
FMT Provider: Yes
VISIT WEBSITE >

Dr. John Manaloor, MD

Assistant Professor of Clinical Pediatrics
The Children’s Hospital of San Antonio
333 N Santa Rosa St
San Antonio, 78207
877-465-1856
FMT Provider: No
VISIT WEBSITE >

Regulation

C. diff Infections

Total Reported Cases: 5716
Hospital Onset: 5716
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.64
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: No
Data Publicly Available: No
Data Validated: No
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Not available
STATUTE >

State Contact

Shawn Tupy MT, MBA
Healthcare Safety Group Manager
Texas Department of State Health Services
Emerging and Acute Infectious Disease Branch
1100 W 49th Street
Austin, 78756
(512) 776-6355
EMAIL SHAWN TUPY MT, MBA >

CLINICAL TRIALS

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

BEETHOVEN

Official Title: A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER
Trial No. NCT07282665
Type: Interventional
Recruitment: Recruiting
Sponsor: Pfizer
Contact: See trial website for site-specific contacts
Gender: All
Age: 65 Years and older